DOI QR코드

DOI QR Code

High Resolution Melting Curve Assay for Detecting rs12979860 IL28B Polymorphisms Involved in Response of Iranian Patients to Chronic Hepatitis C Treatment

  • Fateh, Abolfazl (Department of Virology, School of Public Health, Tehran University of Medical Sciences) ;
  • Aghasadeghi, Mohammad Reza (Department of Hepatitis and AIDS, Pasteur Institute of Iran) ;
  • Keyvani, Hossein (Departments of Virology, Iran University of Medical Sciences) ;
  • Mollaie, Hamid Reza (Departments of Virology, Iran University of Medical Sciences) ;
  • Yari, Shamsi (Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran) ;
  • Tasbiti, Ali Reza Hadizade (Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran) ;
  • Ghazanfari, Morteza (Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran) ;
  • Monavari, Seyed Hamid Reza (Departments of Virology, Iran University of Medical Sciences)
  • Published : 2015.03.18

Abstract

Background: A recent genome-wide association study (GWAS) on patients with chronic hepatitis C (CHC) treated with peginterferon and ribavirin (pegIFN-${\alpha}$/RBV) identified a single nucleotide polymorphism (SNP) on chromosome 19 (rs12979860) which was strongly associated with a sustained virological response (SVR). The aim of this study was twofold: to study the relationship between IL28B rs12979860 and sustained virological response (SVR) to pegIFN-${\alpha}$/RVB therapy among CHC patients and to detect the rs12979860 polymorphism by high resolution melting curve (HRM) assay as a simple, fast, sensitive, and inexpensive method. Materials and Methods: The study examined outcomes in 100 patients with chronic hepatitis C in 2 provinces of Iran from December 2011 to June 2013. Two methods were applied to detect IL28B polymorphisms: PCR-sequencing as a gold standard method and HRM as a simple, fast, sensitive, and inexpensive method. Results: The frequencies of IL28B rs12979860 CC, CT, and TT alleles in chronic hepatitis C genotype 1a patients were 10% (10/100), 35% (35/100), and 6% (6/100) and in genotype 3a were 13% (13/100), 31% (31/100), and 5% (5/100), respectively. In genotype 3a infected patients, rs12979860 (CC and CT alleles) and in genotype 1a infected patients (CC allele) were significantly associated with a sustained virological response (SVR). The SVR rates for CC, CT and TT (IL28B rs12979860) were 18%, 34% and 4%, respectively. Multiple logistic regression analysis identified two independent factors that were significantly associated with SVR: IL-28B genotype (rs 12979860 CC vs TT and CT; odds ratio [ORs], 7.86 and 4.084, respectively), and HCV subtype 1a (OR, 7.46). In the present study, an association between SVR rates and IL28B polymorphisms was observed. Conclusions: The HRM assay described herein is rapid, inexpensive, sensitive and accurate for detecting rs12979860 alleles in CHC patients. This method can be readily adopted by any molecular diagnostic laboratory with HRM capability and will be clinically beneficial in predicting treatment response in HCV genotype 1 and 3 infected patients. In addition, it was demonstrated that CC and CT alleles in HCV-3a and the CC allele in HCV-1a were significantly associated with response to pegIFN-${\alpha}$/RBV treatment. The present results may help identify subjects for whom the therapy might be successful.

Keywords

Chronic hepatitis C;single nucleotide polymorphism;sustained virological response

References

  1. Afshar RM, Mollaie HR (2012). Detection of HBV resistance to lamivudine in patients with chronic hepatitis B using zip nucleic acid probes in Kerman, southeast of Iran. Asian Pac J Cancer Prev, 13, 3657-61. https://doi.org/10.7314/APJCP.2012.13.8.3657
  2. Akkarathamrongsin S, Thong VD, Payungporn S, et al (2014). IFNL3 (IL28B) and IFNL4 polymorphisms are associated with treatment response in Thai patients infected with HCV genotype 1, but not with genotypes 3 and 6. J Med Virol, 86, 1482-90. https://doi.org/10.1002/jmv.23957
  3. Alavian SM, Tabatabaei SV, Keshvari M, et al (2010). Peginterferon alpha-2a and ribavirin treatment of patientswith haemophilia and hepatitis C virus infection: a singlecentre study of 367 cases. Liver Int, 30, 1173-80. https://doi.org/10.1111/j.1478-3231.2010.02296.x
  4. Altuglu I, Soyler I, Ozacar T, et al (2008). Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in Western Turkey. Int J Infect Dis, 12, 239-44. https://doi.org/10.1016/j.ijid.2007.07.003
  5. Antaki N, Craxi A, Kamal S, et al (2010). Theneglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int, 30, 342-55. https://doi.org/10.1111/j.1478-3231.2009.02188.x
  6. Asselah T, Bieche I, Paradis V, et al (2007). Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis, 27, 13-27. https://doi.org/10.1055/s-2006-960168
  7. Balagopal A, Thomas DL, Thio CL (2010). IL28B and the control of hepatitis C virus infection. Gastroenterology, 139, 1865-76. https://doi.org/10.1053/j.gastro.2010.10.004
  8. Beinhardt S, Rutter K, Stattermayer AF, Ferenci P (2013). Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus. Clin Infect Dis, 56, 118-122. https://doi.org/10.1093/cid/cis843
  9. Chen X, Sullivan PF (2003). Single nucleotide polymorphism genotyping: biochemistry, protocol, cost and throughput. Pharmacogenomics J, 3, 77-96. https://doi.org/10.1038/sj.tpj.6500167
  10. Dai CY, Huang JF, Hsieh MY, et al (2009). Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol, 50, 712-8. https://doi.org/10.1016/j.jhep.2008.12.017
  11. Domagalski K, Pawlowska M, Tretyn A, et al (2013). Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4. Eur J Clin Microbiol Infect Dis, 32, 745-54. https://doi.org/10.1007/s10096-012-1799-z
  12. Eslam M, Leung R, Romero-Gomez M, et al (2014). IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. J Hepatol, 61, 235-41. https://doi.org/10.1016/j.jhep.2014.03.039
  13. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2014. From: http://www.easl.eu/_newsroom/latest-news/easlrecommendations-on-treatment-of-hepatitis-c-2014
  14. Falleti E, Bitetto D, Fabris C, et al (2011). Role of interleukin 28B rs12979860 C/T polymorphism on the histological outcome of chronic hepatitis C: relationship with gender and viral genotype. J Clin Immunol, 31, 891-9. https://doi.org/10.1007/s10875-011-9547-1
  15. Ge D, Fellay J, Thompson AJ, et al (2009). Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 461, 399-401 https://doi.org/10.1038/nature08309
  16. Ghany MG, Nelson DR, Strader DB, et al (2011). American association for study of liver D. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 54, 1433-44. https://doi.org/10.1002/hep.24641
  17. Ghany MG, Strader DB, Thomas DL, Seeff LB (2009). Diagnosis, management, and treatment of hepatitis C: an update. Hepatology, 49, 1335-74. https://doi.org/10.1002/hep.22759
  18. Grebely J, Petoumenos K, Hellard M, et al (2010). Potential role for interleukin-28B genotype in treatment decisionmaking in recent hepatitis C virus infection. Hepatology, 52, 1216-24. https://doi.org/10.1002/hep.23850
  19. Kau A, Vermehren J, Sarrazin C (2008). Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol, 49, 634-51. https://doi.org/10.1016/j.jhep.2008.07.013
  20. Keyvani H, Alizadeh AH, Alavian SM, et al (2007). Distribution frequency of hepatitis C virus genotypes in 2231 patients in Iran. Hepatol Res, 37, 101-3. https://doi.org/10.1111/j.1872-034X.2007.00015.x
  21. Keyvani H, Fazlalipour M, Monavari SH, et al (2012). Hepatitis C virus--proteins, diagnosis, treatment and new approaches for vaccine development. Asian Pac J Cancer Prev, 13, 5931-49.
  22. Mangia A, Thompson AJ, Santoro R, et al (2010). An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology, 139, 821-7. https://doi.org/10.1053/j.gastro.2010.05.079
  23. Martinez-Gomez LE, Chavez-Tapia NC, Burguete-Garcia AI, et al (2012). IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population. Ann Hepatol, 11, 876-81.
  24. Melis R, Fauron C, McMillin G, et al (2011). Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response. J Mol Diagn, 13, 446-51. https://doi.org/10.1016/j.jmoldx.2011.03.008
  25. Moghaddam A, Melum E, Reinton N, et al (2011). IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology, 53, 746-54. https://doi.org/10.1002/hep.24154
  26. Namazee N, Sali S, Asadi S, et al (2012). Real response to therapy in chronic hepatitis C virus patients: a study from Iran. Hepat Mon, 12, 6151.
  27. Poon KS, Ho SS, Tang JW, et al (2012). Targeting both rs12979860 and rs8099917 polymorphisms with a singletube high-resolution melting assay for IL28b genotyping. J Clin Microbiol, 50, 3353-5. https://doi.org/10.1128/JCM.01718-12
  28. Pourhoseingholi MA, Fazeli Z, Zali MR, et al (2010). Burden of hepatocellular carcinoma in Iran; Bayesian projection and trend analysis. Asian Pac J Cancer Prev, 11, 859-62.
  29. Rauch A, Kutalik Z, Descombes P, et al (2010). Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology, 138, 1338-45. https://doi.org/10.1053/j.gastro.2009.12.056
  30. Sajid A, Ayaz A, Raham Sh, et al. Genotyping of HCV RNA Reveals That 3a Is the Most Prevalent Genotype in Mardan, Pakistan. Advances in Virology, 2014, 1-5.
  31. Samimi-Rad K, Nategh R, Malekzadeh R, et al (2004). Molecular epidemiology of hepatitis C virus in Iran as reflected by phylogenetic analysis of the NS5B region. J Med Virol, 74, 246-52. https://doi.org/10.1002/jmv.20170
  32. Sarrazin C, Susser S, Doehring A, et al (2011). Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol, 54, 415-21. https://doi.org/10.1016/j.jhep.2010.07.041
  33. Sharafi H, Pouryasin A, Alavian SM, et al (2012). Development and validation of a simple, rapid and inexpensive PCR-RFLP Method for genotyping of common IL28B polymorphisms: A useful pharmacogenetic tool for prediction of hepatitis C treatment response. Hepat Mon, 12, 190-5.
  34. Shi X, Pan Y, Wang M, et al (2012). IL28B genetic variation is associated with spontaneous clearance of hepatitis C virus, treatment response, serum IL-28B levels in Chinese population. PLoS One, 7, 37054. https://doi.org/10.1371/journal.pone.0037054
  35. Su CH, Lin Y, Cai L (2013). Genetic factors, viral infection, other factors and liver cancer: an update on current progress. Asian Pac J Cancer Prev, 14, 4953-60. https://doi.org/10.7314/APJCP.2013.14.9.4953
  36. Suppiah V, Moldovan M, Ahlenstiel G, et al (2009). IL28B is associated with response to chronic hepatitis C interferonalpha and ribavirin therapy. Nat Genet, 41, 1100-4. https://doi.org/10.1038/ng.447
  37. Thomas DL, Thio CL, Martin MP, et al (2009). Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature, 461, 798-801. https://doi.org/10.1038/nature08463
  38. Tsubota A, Kiyotaka F, Yoshihisa N, et al (2011). Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol, 17, 419-432. https://doi.org/10.3748/wjg.v17.i4.419
  39. Viazov S, Kuzin S, Paladi N, et al (1997). Hepatitis C virus genotypes in different regions of the former Soviet Union (Russia, Belarus, Moldova, and Uzbekistan). J Med Virol, 53, 36-40. https://doi.org/10.1002/(SICI)1096-9071(199709)53:1<36::AID-JMV7>3.0.CO;2-R
  40. Wohnsland A, Hofmann WP, Sarrazin C (2007). Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev, 20, 23-38. https://doi.org/10.1128/CMR.00010-06
  41. Yang JD, Roberts LR (2010). Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol, 7, 448-58. https://doi.org/10.1038/nrgastro.2010.100
  42. Zali MR, Mayumi M, Raoufi M, et al (2000). Hepatitis C virus genotypes in the Islamic Republic of Iran: a preliminary study. East Mediterr Health J, 6, 372-7.
  43. Zekri AR, Salama H, Medhat E, et al (2014). IL28B rs12979860 Gene polymorphism in Egyptian patients with chronic liver disease infected with HCV. Asian Pac J Cancer Prev, 15, 7213-8. https://doi.org/10.7314/APJCP.2014.15.17.7213

Cited by

  1. Genetic Variation in Interleukin-28B and Response to Peg-IFNα-2a/RBV Combination Therapy in Patients with Hepatitis C Virus Infection vol.10, pp.1, 2016, https://doi.org/10.5812/jjm.39178
  2. IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C vol.162, pp.1, 2017, https://doi.org/10.1007/s00705-016-3095-1
  3. EGFR rs11506105 and IFNL3 SNPs but not rs8099917 are strongly associated with treatment responses in Iranian patients with chronic hepatitis C vol.18, pp.3, 2017, https://doi.org/10.1038/gene.2017.12
  4. First detection of human hepegivirus-1 (HHpgV-1) in Iranian patients with hemophilia vol.8, pp.1, 2018, https://doi.org/10.1038/s41598-018-23490-4
  5. Human Genetic Predisposition to Diseases Caused by Viruses from Flaviviridae Family vol.52, pp.2, 2018, https://doi.org/10.1134/S0026893317050223